Dropped GLP-1 Coverage Leaves Workers 'Terrified'
Key Points:
- Employers are increasingly reducing or eliminating coverage for GLP-1 weight-loss drugs like Wegovy and Zepbound due to rising health care costs, with coverage among large employers dropping from 72% in 2025 to 60% this year.
- Major companies such as Starbucks, UPS, PepsiCo, and Comcast are among those scaling back benefits for these medications, citing rapid expense growth as a key reason.
- Health experts and obesity advocates warn that cutting coverage creates disparities, leaving only those who can afford high out-of-pocket costs able to access treatment for a chronic disease.
- Patients report resorting to discount programs, dose stretching, or discontinuing medication altogether, expressing fear about the potential negative impact on their health.
- The situation highlights a growing tension between employer cost management and patient access to effective weight-loss treatments.